Aldeyra Therapeutics/$ALDX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Aldeyra Therapeutics
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
Ticker
$ALDX
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
8
Website
ALDX Metrics
BasicAdvanced
$302M
-
-$0.97
0.90
-
Price and volume
Market cap
$302M
Beta
0.9
52-week high
$7.20
52-week low
$1.14
Average daily volume
1.2M
Financial strength
Current ratio
6.491
Quick ratio
6.357
Long term debt to equity
24.075
Total debt to equity
24.476
Interest coverage (TTM)
-32.00%
Profitability
EBITDA (TTM)
-60.901
Management effectiveness
Return on assets (TTM)
-32.60%
Return on equity (TTM)
-65.19%
Valuation
Price to book
4.77
Price to tangible book (TTM)
4.77
Price to free cash flow (TTM)
-6.586
Free cash flow yield (TTM)
-15.18%
Free cash flow per share (TTM)
-0.767
Growth
Earnings per share change (TTM)
90.65%
3-year earnings per share growth (CAGR)
-4.34%
10-year earnings per share growth (CAGR)
-8.17%
What the Analysts think about ALDX
Analyst ratings (Buy, Hold, Sell) for Aldeyra Therapeutics stock.
ALDX Financial Performance
Revenues and expenses
ALDX Earnings Performance
Company profitability
ALDX News
AllArticlesVideos
Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease
Business Wire·2 weeks ago
Aldeyra Therapeutics Receives Special Protocol Assessment Agreement Letter from the U.S. Food and Drug Administration for ADX-2191 for the Treatment of Primary Vitreoretinal Lymphoma
Business Wire·1 month ago
Aldeyra Therapeutics to Participate in the 2025 Jefferies Global Healthcare Conference
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Aldeyra Therapeutics stock?
Aldeyra Therapeutics (ALDX) has a market cap of $302M as of August 01, 2025.
What is the P/E ratio for Aldeyra Therapeutics stock?
The price to earnings (P/E) ratio for Aldeyra Therapeutics (ALDX) stock is 0 as of August 01, 2025.
Does Aldeyra Therapeutics stock pay dividends?
No, Aldeyra Therapeutics (ALDX) stock does not pay dividends to its shareholders as of August 01, 2025.
When is the next Aldeyra Therapeutics dividend payment date?
Aldeyra Therapeutics (ALDX) stock does not pay dividends to its shareholders.
What is the beta indicator for Aldeyra Therapeutics?
Aldeyra Therapeutics (ALDX) has a beta rating of 0.9. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.